Posts

Effect of Marihuana on Intraocular and Blood Pressure in Glaucoma

Author: John C.Merritt MD, William J.Crawford PhD, Paul C.Alexander MD, Alfred L.Anduze MD, Solomon S.Gelbart MD Published in Science Direct March 1980 Abstract Marihuana inhalation was accompanied by increased heart rate and decreased intraocular and blood pressure in 18 subjects with heterogenous glaucomas. The hypotensive effects appeared in 60 to 90 minutes as the decrease in…

Experiences with Administration of Marihuana to Glaucoma Patients

Author: Robert S. HeplerRobert J. Petrus Published in Springer Link  1976 Abstract In 1971 Hepler and Frank reported reduction in intraocular pressure occurring after healthy young adults smoked marihuana. These initial observations led to additional studies designed to compare the pressure-reducing effects of placebo, smoked marihuana, and injected THC. Consistent, statistically-significant pressure reduction was observed in…

Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol

Author: Brenda K.Colasanti, Charles R. Craig, R. David Allara Published in Science Direct September 1984 Abstract Cannabinol or cannabigerol was administered to cats topically in doses of 250, 500 and 1000 μg as a single drop or chronically via osmotic minipumps (20 μg hr−1) over a period of 9 days. While cannabinol had a modest…

A national survey of US emergency medicine physicians on their knowledge regarding state and federal cannabis laws.

Author: Kevin M. Takakuwa, Frances S. Shofer, and Raquel M. Schears. Published in Mary Ann Liebert, Inc, Publishers February 2020 Abstract Introduction Medical cannabis laws have been passed in 33 U S States but cannabis remains federally illegal Eleven states additionally allow for adult use recreational Studies report and increase in Emergency Department ED use when…

The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage

Author: Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Published in Mary Ann Liebert, Inc. Publishers January 2020 Abstract Objectives: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site…

Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and Critical Review

Author: Ciara A. Torres, Christopher Medina-Kirchner, Kate Y. O’Malley, and Carl L. Hart Published in Frontiers in Psychology May 2020 Abstract Background Despite limited data demonstrating pronounced negative effects of prenatal cannabis exposure, popular opinion and public policies still reflect the belief that cannabis is fetotoxic. Methods This article provides a critical review of results from…

Cannabis and Psychosis: a Critical Overview of the Relationship

Authors: Charles Ksir, Carl L Hart Published in Current Psychiatry Reports February 2016 Abstract Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific…

A Scoping Review of the Use of Cannabis and Its Extracts as Potential Harm Reduction Strategies: Insights from Preclinical and Clinical Research

Authors: James Siklos-Whillans, Alia Bacchus, Laurie A. Manwell Published in International Journal of Mental Health and Addiction March 2020 Abstract Cannabis as a harm reduction strategy (HRS) is supported by evidence demonstrating its efficacy for pain relief and as a substitution for alcohol, illicit drugs, and pharmaceuticals. Animal models show cannabinoids reduce the effects of opiate…

Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms

Authors: Marieka V. DeVuono, Linda A. Parker Published in Mary Ann Liebert, Inc Publishers June 2020 Abstract Introduction Cannabinoids have long been known for their ability to treat nausea and vomiting. Recent reports, however, have highlighted the paradoxical proemetic effects of cannabinoids. Cannabinoid hyperemesis syndrome (CHS) is characterized by cyclical episodes of nausea and vomiting, accompanied…

The psychoactive compound of Cannabis sativa, Δ(9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover.

Authors: M.A. Costa, B.M. Fonseca, F. Marques, N.A. Teixeira, G. Correia-da-Silva
Toxicology, 6 August 2015

The noxious effects of cannabis consumption for fertility and pregnancy outcome are recognized for years. Its consumption during gestation is associated with alterations in foetal growth, low birth weight and preterm labor. The main psychoactive molecule of cannabis, Δ(9)-tetr…

PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.

Authors: George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, January-March 2014

BACKGROUND: New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report…

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Authors: Celia J.A. Morgan, Tom P. Freeman, Gráinne L. Schafer, H. Valerie Curran
Neuropsychopharmacology, August 2010

Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabino…